Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of neurodegenerative conditions that are transmissible, progressive and uniformly fatal. They occur in both humans and animals. Prion disease came to prominence after the development of bovine spongiform encephalopathy (BSE) in the 1980s and, consequently, variant Creutzfeldt -Jakob disease (vCJD) in the 1990s. BSE and vCJD have had far reaching implications for the UK economy but especially for the farming and healthcare sectors. With the advent of BSE, prices for beef originating in the UK fell dramatically and this proved crippling to much of the UK farming community. Although the peak of the vCJD epidemic appears to have passed, prevalence studies suggest that around 1 in 3000 UK adults may be infected with vCJD prions (http://www.hpa. org.uk/hpr/archives/2011/news3611.htm#cjd). As there is currently no treatment for vCJD, considerable effort has been put into disease prevention. Difficulties in the diagnosis of vCJD, lack of treatment, and inability of conventional sterilization to completely remove prion protein from surgical instruments have also resulted in significant changes in healthcare delivery. Although the implications of vCJD for the delivery of anaesthesia are limited, it is important that anaesthetists understand how to identify patients at high risk of vCJD and are aware of the relevant precautionary measures that must be taken. 
Pathophysiology of prion disease

Animal forms of prion disease
Scrapie is a TSE that occurs in sheep and goats. Classical scrapie has been recognized in the UK for over two centuries. Infected animals display symptoms of skin irritation and behavioural changes such as irritability and ataxia. The disease progresses rapidly over a few months and the affected animal eventually becomes recumbent, wasted, and dies.
In 1986, a new transmissible, food-borne, spongiform encephalopathy, BSE, was identified. The BSE epidemic partly resulted from a change in the rendering process of meat and bone meal derived from animal carcasses which was used as a high-protein feed supplement for cattle, particularly dairy herds. Although these process changes may explain the spread of prion infection across UK cattle herds, the original trigger for the epidemic is uncertain. The disease has been identified in several countries but the greatest numbers of cases are found in the UK. At the peak of the epidemic in 1992, there were 37 000 recorded cases of BSE, but the total number of cases has been estimated at over 6 million. Since then the numbers have dwindled to just a few cases each year. BSE manifests itself with signs of aggression, ataxia, and muscle twitching. The disease progresses rapidly and death occurs within months.
Human forms of prion disease
A spongiform encephalopathy known as kuru was prevalent in cannibalistic tribes, mainly Fore speaking groups in the Eastern Highlands of Papua New Guinea, in the 1950s, although the disease had been recognized by the Fore people more than 50 years earlier. The clinical
Key points
Creutzfeldt -Jakob disease is caused by the accumulation of abnormal prion protein in the brain and lymphoreticular tissues.
Variant Creutzfeldt -Jakob (vCJD) disease can only be diagnosed definitively by tonsillar or brain biopsy, but a blood test to support early diagnosis is now available.
Patients at increased risk of vCJD must be identified and informed that they may pose a risk to public health. presentation is of cerebellar ataxia, with or without dementia, which typically develops later in the disease.
Sporadic CJD
Sporadic CJD (sCJD) accounts for 85% of all human prion disease. It predominantly affects those of middle to old age, with a mean age of death in the late 60s. The cause of the disease remains unknown. Patients classically present with memory impairment and cognitive decline accompanied by neurological features such as ataxia, extrapyramidal and pyramidal signs, and myoclonus. The clinical course is usually rapidly progressive and the patient typically becomes bedbound, akinetic, and mute within weeks to months. The majority of cases are fatal within 6 months.
Inherited prior disease
Inherited prion disease accounts for a large proportion of the remaining 15% of human disease. 1 There are over 30 mutations affecting the prion protein gene giving increase to diverse disease phenotypes, with an autosomal dominant pattern of inheritance.
There is reduced penetrance with some mutations.
Iatrogenic prion disease
Iatrogenic prion disease can occur secondary to infection from neurosurgical procedures, corneal grafting, blood transfusions, human cadaveric growth hormone (hGH), and human pituitary gonadotrophin. The disease phenotype is dependent on the route of transmission. Typically, cases of peripheral exposure, such as that following hGH usage, present with a long incubation time, and incubation times up to 35 years have been identified. The clinical features are those of a progressive cerebellar syndrome with dementia appearing later in the disease. Exposure from tissue closer to the brain, such as after implantation of human dura mater, presents with a rapidly progressive dementia similar to that seen in sCJD.
Variant Creutzfeldt-Jakob disease vCJD is caused by the same prion strain that causes BSE in cattle, leading to the conclusion that human transmission is from dietary exposure to BSE prions. 2 The number of clinical cases of vCJD is only around 200 to date, a small number in comparison with the large number of people who were potentially exposed to BSE prions. The majority of cases have been in the UK. Genetic susceptibility factors are known to play a part in the development of the disease. The first cases of vCJD were reported in 1995, 12 years after the identification of BSE. 3, 4 However, as more cases were identified, atypical clinical and pathological features were described, and this new disease was named new vCJD. 5 The peak of the epidemic is likely to have been in 2000, which gives an estimate of an incubation period based on BSE to vCJD peaks of 8 years. The number of vCJD cases has dwindled to 1-2 cases per year after several public health initiatives including the prevention of animal matter with potentially high prion levels, namely central nervous system tissue and lymphoreticular tissue, entering the food chain. Although the peak of the vCJD epidemic appears to have passed, prevalence studies suggest that around 1 in 3000 UK adults may be infected with vCJD prions (http://www.hpa.org.uk/hpr/archives/ 2011/news3611.htm#cjd).
In contrast to sCJD, vCJD typically affects a younger population, with a median (range) age of onset of 28 (12-74) years. The vCJD phenotype is a less rapidly progressive disease, with the majority of cases featuring psychiatric manifestations and peripheral pain or paraesthesia early in the disease. The psychiatric and behavioural features of vCJD include anxiety, dysphoria, apathy, withdrawal, and insomnia. Visual or auditory hallucinations and delusions are also common. It is thus not unusual for patients to be diagnosed with a depressive or psychotic illness before cognitive or physical impairment becomes apparent. Neurological signs may occur early but can also develop later in the disease. Early neurological features include memory impairment, cerebellar ataxia, and dysarthria. As the disease progresses, cognitive impairment, movement abnormalities such as chorea and dystonia, ataxia, myoclonus and pyramidal signs predominate. Disease duration is 14 months.
Diagnosis
vCJD cannot be diagnosed with absolute certainty on clinical criteria alone, and neuropathological confirmation is usually required (see below). However, a combination of symptoms and signs assist with defining possible, probable, and definite cases of vCJD and these have been categorized by the World Health Organization (Table 1) .
Magnetic resonance imaging
Magnetic resonance imaging is a valuable diagnostic tool as it identifies features that are highly specific to vCJD. Many, but not all, patients present with the classic 'pulvinar' or 'hockey stick' sign ( Fig. 1) . These are high signal changes in the pulvinar and dorsomedial areas of the thalamus best seen on FLAIR and DWI sequences, but also evident in 71% of patients on T2-weighted imaging. 6 
Electroencephalography
The electroencephalogram in vCJD may show generalized slowing but, unlike in sCJD, periodic sharp wave complexes are not typically seen.
Cerebrospinal fluid examination
The cerebrospinal fluid (CSF) cell count and protein are usually normal. However, some proteins, such as 14-3-3, tau, and S100 beta proteins, may be raised. Since these are markers of neurodegeneration generally and not specific to prion disease, they are not diagnostic.
Prion blood test
A blood test has recently been developed by the NHS National Prion Clinic working with the MRC Prion Unit which can detect prion protein in the blood of patients with vCJD. The blood test
Creutzfeldt -Jakob disease has a sensitivity of 70% and to date there have been no false positives in non-prion disease patients. 7 
Histology
Examination of tissue samples, either of lymphoreticular (e.g. tonsillar biopsy) during life or brain tissue after death, remains the gold standard for the diagnosis of vCJD. Abnormal prion protein, PrP Sc , is identified within lymphoid tissues when stained with PrP immunohistochemistry. The typical neuropathology seen in prion disease is spongiform change, gliosis, and neuronal loss accompanied by deposits of PrP as 'florid' plaques (Fig. 2) . The sensitivity and specificity of tonsillar biopsy is to date 100%. 8 Histological confirmation should be considered in patients when the clinical diagnosis of vCJD is uncertain, and other neurodegenerative conditions have not been excluded.
Treatment
Presently, there is no treatment for vCJD and management is supportive. The disease is ultimately fatal. A large number of compounds have been found to restrict PrP Sc production both in vitro and in a limited number of animal studies. Although a number of such agents have been given to patients with CJD, none has proved effective in altering the natural history of any type of CJD. The largest study found that quinacrine, a drug used to treat malaria and some arthritic conditions, had no effect on mortality. 9 Anecdotal reports have suggested that intracerebral administration of pentosan polysulphate is associated with a prolonged disease duration in vCJD, with patients surviving in an akinetic mute state for up to 6 years. 10 The long disease duration is possibly confounded by artificial feeding and vigorous management of infection in such reports.
Monoclonal antibodies (ICSM-18) derived from PrP C null animals have shown considerable promise in animal models of prion disease when administered extra cerebrally, particularly if given before the onset of neurological symptoms. These antibodies have now been humanized and it is anticipated that clinical trials will begin within 1-2 years.
Fig 1
The FLAIR, MRI sequence shows hyperintensity in the basal ganglia (A) and also the characteristic pulvinar (hockey stick) sign in a patient with vCJD (B), this is defined as hyperintensity in the pulvinar and dorsomedial areas of the thalamus greater than that seen in the putamen. Prevention/limitation of the spread of CJD There are many initiatives that have been introduced to prevent or limit the spread of CJD. Important in this regard, CJD has been a notifiable disease in the UK since June 1988, allowing monitoring and surveillance of the epidemic.
Prevention of prion protein entering the food chain
Ruminants were previously fed animal-derived protein supplements potentially infected with BSE and this practice ceased in 1988. Feeding restrictions were extended in 1992 when a ban was placed on mammalian offal being fed to farm animals. Thus, tissues at higher risk of containing prion material, namely the brain, spinal cord, tonsils, thymus, and intestine (Table 2) , are now removed at slaughter and not incorporated into mammalian feed. Finally, no product of any animal shown to exhibit TSE can now become part of the food chain. This applies to tissues considered to be of low infectivity risk and applies to both animal and human food chains.
Vaccines
The pharmaceuticals industry has historically used bovine material in the manufacture of vaccines. This practice can now only occur in unavoidable circumstances, in which case the bovine material must be sourced from countries which are TSE-free and where stringent surveillance programmes are in place.
Hormone replacement therapy
Growth hormone from the anterior pituitary gland of human cadavers and human pituitary gonadotrophin were historically used for replacement therapy. Synthetic products are now used.
Identification of individuals at risk to public health
Individuals regarded as having increased risk of CJD, defined as those with a greater than 1% risk of infection, need to be identified to minimize the risk of transmission. 11 Broadly speaking, this includes those who have received dura mater grafts or certain hormone replacement therapy, and individuals with a genetic predisposition to CJD.
Use of blood products and tissue
Since 1997, the theoretical risk of transmission of vCJD via blood products has been considered and a number of measures have been put in place to minimize the risk of transmission via this route.
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These include: † a ban on blood donation by an individual who has had a blood transfusion since July 2004; † a ban on donation of blood, organs, tissue, bone marrow, sperm, or eggs by an individual at increased risk of CJD; 
Consequences for anaesthetists
Anaesthetizing patients with CJD, or those at increased risk of the disease, is essentially similar to routine practice. The areas of importance are the identification of patients at increased risk of CJD and the use of disposable airway equipment. Practical steps and issues for consideration by the anaesthetist are summarized in Table 3 . Disposal of surgical instruments also requires special attention.
Identification of patients at increased risk of CJD
Identification of patients at increased risk of CJD is dependent on accurate history-taking. 13 The important risk areas can be divided into three broad categories.
Related to previous blood transfusion
All patients at risk of CJD from a previous blood transfusion should have been notified by relevant authorities. These include those who received fractionated blood components sourced from blood donors in the UK between 1980 and 2001. Blood components are pooled donations from several donors so the risk of transmission of infection is significantly higher than for red cells which are derived from a single donor. Patients who received red cells or other blood products from donors who later developed CJD are also at increased risk of CJD.
Related to previous surgery
Patients considered at high risk of CJD include those who have undergone surgery where surgical instruments have previously been used on a patient who later developed CJD, those who had a dural graft inserted during intracranial or intradural spinal surgery before August 1992, and patients who have received an organ or tissue from a donor who later developed CJD. All will have been notified about their risk status.
Related to medical issues
Individuals treated with growth hormone sourced from humans before 1985, gonadotrophin sourced from humans before 1973 and those with a genetic risk of developing CJD are also perceived to be at high risk of CJD infection.
Airway equipment
With the advent of CJD, there has been a need for all airway equipment to become single-use only. In most centres, disposable laryngoscope blades and single-use laryngeal masks are now in routine use. While fibreoptic intubating endoscopes have until recently been sterilized and reused, disposable endoscopes are now available. Reusable endoscopes must be traceable to assist with CJD monitoring and surveillance.
Surgical instruments
Abnormal prion protein is not completely removed by conventional sterilization methods, including autoclaving. This poses problems for transmission of prion disease by contaminated surgical equipment. This is relevant when a patient with CJD, or at increased risk of CJD, has a procedure involving tissue which is deemed of medium or high risk (Table 2 and http://www.dh.gov.uk/ab/ACDP/ TSEguidance/index.htm).
14 Decisions around the use of surgical instruments are complex and must be made on an individual patient basis, taking into account: † the likelihood of the patient having CJD;
† the tissues involved in the operation and whether these are deemed likely to harbour high, medium, or low levels of prion infection; † the type of prion disease-patients with vCJD, or those at-risk of vCJD, may have lymphoreticular and central nervous system involvement; † the feasibility of performing surgery using all or some disposable instruments; † the possibility of destroying parts or some of the instruments which are in contact with high-risk tissue if disposable instruments cannot be used. The World Health Organization surgical safety checklist is a tool used to improve surgical safety by reducing operative mortality and complications and is now implemented routinely throughout the UK. In the final part of the checklist, clinicians are asked to consider whether there is a risk of CJD transmission during the operation. In general terms, if the patient is considered to be at increased risk of CJD, and the operation involves tissues at high or medium risk of CJD infectivity, consideration must be given to using single-use instruments, quarantining instruments, or destroying instruments. However, in tissues considered to be low risk, instruments can be sterilized and reutilized in a conventional manner, even if the patient is considered to be at high risk of CJD. Further information is available at http://www.dh.gov.uk/ab/ACDP/ TSEguidance/index.htm and the National Prion Clinic (www.nationalprionclinic.org) can also offer individual advice.
Some single-use surgical instruments are more expensive, of inferior quality or both when compared with standard, reusable instruments. Where disposable instruments are concerned, NICE recommends only the use of those disposable instruments that are of an equally high standard to reusable ones.
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